{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:48:47Z","timestamp":1756464527027},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>[<jats:sup>223<\/jats:sup>Ra]RaCl<jats:sub>2<\/jats:sub> is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [<jats:sup>223<\/jats:sup>Ra]RaCl<jats:sub>2<\/jats:sub> is excreted via the intestine into feces, and some is absorbed from the intestine into the blood, which may be undesirable in terms of the exposure to radiation. Recently, we showed that a complex of <jats:italic>myo<\/jats:italic>-inositol-hexakisphosphate (InsP6) with zinc is a useful decorporation agent against radiostrontium. In this study, we hypothesized that Zn-InsP6 could bind to not only strontium but also to radium, and could inhibit the absorption of radium from the intestine. In in vitro binding experiments, Zn-InsP6 showed a high binding affinity for radium. In in vivo biodistribution experiments by intravenous injection of [<jats:sup>223<\/jats:sup>Ra]RaCl<jats:sub>2<\/jats:sub> after treatment of Zn-InsP6, mice treated with Zn-InsP6 showed significantly lower bone accumulation of radioactivity (34.82\u2009\u00b1\u20091.83%Dose\/g) than the mice in the non-treatment control group (40.30\u2009\u00b1\u20092.78%Dose\/g) at 48\u00a0h postinjection. These results indicate that Zn-InsP6 bound radium in the intestine and inhibited the absorption of radium into the blood. Therefore, the insoluble Zn-InsP6 complex has high potential to decrease the side effects of [<jats:sup>223<\/jats:sup>Ra]RaCl<jats:sub>2<\/jats:sub>.<\/jats:p>","DOI":"10.1038\/s41598-020-68846-x","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T14:23:54Z","timestamp":1594995834000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases"],"prefix":"10.1038","volume":"10","author":[{"given":"Kazuma","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Mishiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Odani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"68846_CR1","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman, R. E. Skeletal complications of malignancy. Cancer 80, 1588\u20131594 (1997).","journal-title":"Cancer"},{"key":"68846_CR2","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.2174\/092986712801215865","volume":"19","author":"K Ogawa","year":"2012","unstructured":"Ogawa, K. & Washiyama, K. Bone target radiotracers for palliative therapy of bone metastases. Curr. Med. Chem. 19, 3290\u20133300 (2012).","journal-title":"Curr. Med. Chem."},{"key":"68846_CR3","doi-asserted-by":"publisher","first-page":"676053","DOI":"10.1155\/2015\/676053","volume":"2015","author":"K Ogawa","year":"2015","unstructured":"Ogawa, K. & Ishizaki, A. Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases. Biomed. Res. Int. 2015, 676053 (2015).","journal-title":"Biomed. Res. Int."},{"key":"68846_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"P Hoskin","year":"2014","unstructured":"Hoskin, P. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 15, 1397\u20131406 (2014).","journal-title":"Lancet Oncol."},{"key":"68846_CR5","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","volume":"11","author":"S Nilsson","year":"2005","unstructured":"Nilsson, S. et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 11, 4451\u20134459 (2005).","journal-title":"Clin. Cancer Res."},{"key":"68846_CR6","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2967\/jnumed.115.157123","volume":"56","author":"SJ Chittenden","year":"2015","unstructured":"Chittenden, S. J. et al. A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J. Nucl. Med. 56, 1304\u20131309 (2015).","journal-title":"J. Nucl. Med."},{"key":"68846_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1042\/bj0830025","volume":"83","author":"DM Taylor","year":"1962","unstructured":"Taylor, D. M., Bligh, P. H. & Duggan, M. H. The absorption of calcium, strontium, barium and radium from the gastrointestinal tract of the rat. Biochem. J. 83, 25\u201329 (1962).","journal-title":"Biochem. J."},{"key":"68846_CR8","doi-asserted-by":"publisher","first-page":"e0148080","DOI":"10.1371\/journal.pone.0148080","volume":"11","author":"K Ogawa","year":"2016","unstructured":"Ogawa, K. et al. Evaluation of chlorella as a decorporation agent to enhance the elimination of radioactive strontium from body. PLoS ONE 11, e0148080 (2016).","journal-title":"PLoS ONE"},{"key":"68846_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1248\/cpb.c16-00792","volume":"65","author":"K Ogawa","year":"2017","unstructured":"Ogawa, K. et al. Complexes of myo-Inositol-Hexakisphosphate (IP6) with zinc or lanthanum for the decorporation of radiocesium. Chem. Pharm. Bull. (Tokyo) 65, 261\u2013267 (2017).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"68846_CR10","doi-asserted-by":"publisher","first-page":"e0195067","DOI":"10.1371\/journal.pone.0195067","volume":"13","author":"K Ogawa","year":"2018","unstructured":"Ogawa, K., Aoki, M., Kadono, S. & Odani, A. Complexes of myo-inositol-hexakisphosphate (InsP6) with zinc or lanthanum to enhance excretion of radioactive strontium from the body. PLoS ONE 13, e0195067 (2018).","journal-title":"PLoS ONE"},{"key":"68846_CR11","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/jn\/129.9.1731","volume":"129","author":"K Morita","year":"1999","unstructured":"Morita, K., Matsueda, T., Iida, T. & Hasegawa, T. Chlorella accelerates dioxin excretion in rats. J. Nutr. 129, 1731\u20131736 (1999).","journal-title":"J. Nutr."},{"key":"68846_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/13590840020030267","volume":"11","author":"J Mercola","year":"2001","unstructured":"Mercola, J. & Klinghardt, D. Mercury toxicity and systemic elimination agents. J. Nutr. Environ. Med. 11, 53\u201362 (2001).","journal-title":"J. Nutr. Environ. Med."},{"key":"68846_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1567-5769(03)00082-1","volume":"3","author":"ML Queiroz","year":"2003","unstructured":"Queiroz, M. L., Rodrigues, A. P., Bincoletto, C., Figueiredo, C. A. & Malacrida, S. Protective effects of Chlorella vulgaris in lead-exposed mice infected with Listeria monocytogenes. Int. Immunopharmacol. 3, 889\u2013900 (2003).","journal-title":"Int. Immunopharmacol."},{"key":"68846_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/jmf.2007.0075","volume":"11","author":"JY Shim","year":"2008","unstructured":"Shim, J. Y. et al. Protective effects of Chlorella vulgaris on liver toxicity in cadmium-administered rats. J. Med. Food 11, 479\u2013485 (2008).","journal-title":"J. Med. Food"},{"key":"68846_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4162\/nrp.2009.3.1.15","volume":"3","author":"JA Shim","year":"2009","unstructured":"Shim, J. A., Son, Y. A., Park, J. M. & Kim, M. K. Effect of Chlorella intake on cadmium metabolism in rats. Nutr. Res. Pract. 3, 15\u201322 (2009).","journal-title":"Nutr. Res. Pract."},{"key":"68846_CR16","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/BF02901539","volume":"60","author":"E Graf","year":"1983","unstructured":"Graf, E. Applications of phytic acid. J. Am. Oil Chem. Soc. 60, 1861\u20131867 (1983).","journal-title":"J. Am. Oil Chem. Soc."},{"key":"68846_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1439-0396.2005.00532.x","volume":"89","author":"T Szkudelski","year":"2005","unstructured":"Szkudelski, T. Phytic acid-induced metabolic changes in the rat. J. Anim. Physiol. Anim. Nutr. (Berl) 89, 397\u2013402 (2005).","journal-title":"J. Anim. Physiol. Anim. Nutr. (Berl)"},{"key":"68846_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0891-5849(90)90146-A","volume":"8","author":"E Graf","year":"1990","unstructured":"Graf, E. & Eaton, J. W. Antioxidant functions of phytic acid. Free Radic. Biol. Med. 8, 61\u201369 (1990).","journal-title":"Free Radic. Biol. Med."},{"key":"68846_CR19","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ccr.2007.09.008","volume":"252","author":"F Crea","year":"2008","unstructured":"Crea, F., De Stefano, C., Milea, D. & Sammartano, S. Formation and stability of phytate complexes in solution. Coord. Chem. Rev. 252, 1108\u20131120 (2008).","journal-title":"Coord. Chem. Rev."},{"key":"68846_CR20","doi-asserted-by":"crossref","unstructured":"20Human alimentary tract model for radiological protection. ICRP Publication 100. A report of The International Commission on Radiological Protection. Ann ICRP 36, 25\u2013327, iii (2006).","DOI":"10.1016\/j.icrp.2006.03.001"},{"key":"68846_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ijrobp.2019.07.022","volume":"105","author":"J Taprogge","year":"2019","unstructured":"Taprogge, J. et al. Compartmental model for 223Ra-dichloride in patients with metastatic bone disease from castration-resistant prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 105, 884\u2013892 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"68846_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213\u2013223 (2013).","journal-title":"N. Engl. J. Med."},{"key":"68846_CR23","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1007\/s00259-013-2427-6","volume":"40","author":"JA Carrasquillo","year":"2013","unstructured":"Carrasquillo, J. A. et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 40, 1384\u20131393 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"68846_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clgc.2017.10.022","volume":"16","author":"ND Shore","year":"2018","unstructured":"Shore, N. D. et al. eRADicAte: a prospective evaluation combining Radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer. Clin. Genitourin. Cancer 16, 149\u2013154 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"68846_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/0002-9343(62)90185-7","volume":"32","author":"HQ Woodard","year":"1962","unstructured":"Woodard, H. Q. & Higinbotham, N. L. Development of osteogenic sarcoma in a radium dial painter thirty-seven years after the end of exposure. Am. J. Med. 32, 96\u2013102 (1962).","journal-title":"Am. J. Med."},{"key":"68846_CR26","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.2307\/3579805","volume":"150","author":"SA Fry","year":"1998","unstructured":"Fry, S. A. Studies of U.S. radium dial workers: an epidemiological classic. Radiat Res 150, S21-29 (1998).","journal-title":"Radiat Res"},{"key":"68846_CR27","volume-title":"ICRP Publication 20","author":"Alkaline Earth Metabolism in Adult Man","year":"1973","unstructured":"Alkaline Earth Metabolism in Adult Man. ICRP Publication 20 (Pergamon Press, Oxford., 1973)."},{"key":"68846_CR28","doi-asserted-by":"crossref","unstructured":"Rowland, R. E. Radium in humans: A review of US studies. 246 (United States, 1995).","DOI":"10.2172\/751062"},{"key":"68846_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12149-016-1093-8","volume":"30","author":"K Yoshida","year":"2016","unstructured":"Yoshida, K. et al. Pharmacokinetics of single dose radium-223 dichloride (BAY 88\u20138223) in Japanese patients with castration-resistant prostate cancer and bone metastases. Ann. Nucl. Med. 30, 453\u2013460 (2016).","journal-title":"Ann. Nucl. Med."},{"key":"68846_CR30","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/nsmb1105-940","volume":"12","author":"D Scadden","year":"2005","unstructured":"Scadden, D. When extreme negativity is a positive thing. Nat. Struct. Mol. Biol. 12, 940\u2013941 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"68846_CR31","first-page":"2891","volume":"25","author":"RP Singh","year":"2005","unstructured":"Singh, R. P. & Agarwal, R. Prostate cancer and inositol hexaphosphate: efficacy and mechanisms. Anticancer Res. 25, 2891\u20132903 (2005).","journal-title":"Anticancer Res."},{"key":"68846_CR32","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/jn\/137.4.1101","volume":"137","author":"KM Hambidge","year":"2007","unstructured":"Hambidge, K. M. & Krebs, N. F. Zinc deficiency: a special challenge. J. Nutr. 137, 1101\u20131105 (2007).","journal-title":"J. Nutr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68846-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:17:15Z","timestamp":1670336235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68846-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["68846"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-68846-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11917"}}